- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ArriVent BioPharma: BTIG startet mit Kaufempfehlung wegen Onkologie-Potenzial | 1 | Investing.com Deutsch | ||
| Mi | ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential | 1 | Investing.com | ||
| ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 25.11. | ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug | 3 | Investing.com | ||
| 10.11. | ArriVent BioPharma stock price target raised to $47 from $32 at Clear Street | 4 | Investing.com | ||
| 10.11. | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | ArriVent BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.09. | ArriVent BioPharma appoints Brent Rice as chief commercial officer | 2 | Investing.com | ||
| 22.09. | ArriVent BioPharma beruft Brent Rice zum Chief Commercial Officer | 1 | Investing.com Deutsch | ||
| 22.09. | ArriVent BioPharma, Inc.: ArriVent Appoints Brent S. Rice as Chief Commercial Officer | 257 | GlobeNewswire (Europe) | NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of... ► Artikel lesen | |
| 09.09. | ArriVent reports 16-month PFS for lung cancer drug firmonertinib | 1 | Investing.com | ||
| 09.09. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | ArriVent BioPharma GAAP EPS of -$0.90 misses by $0.20 | 1 | Seeking Alpha | ||
| 11.08. | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | 860 | GlobeNewswire (Europe) | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
| 11.08. | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright | 1 | Investing.com | ||
| 21.07. | ArriVent BioPharma: Oppenheimer bestätigt Rating trotz verzögerter Studiendaten | 2 | Investing.com Deutsch | ||
| 21.07. | ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating | 1 | Investing.com | ||
| 21.07. | ArriVent expects topline data from lung cancer drug trial in early 2026 | 3 | Investing.com | ||
| 21.07. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 67,06 | -0,56 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,08 | +0,72 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| COGENT BIOSCIENCES | 42,110 | +5,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 40,510 | +2,32 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,83 | +0,32 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| LENZ THERAPEUTICS | 18,140 | -25,96 % | LENZ Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,020 | -1,53 % | Amit Munshi joins Arcutis board as founder Chaudhuri retires | ||
| ARCELLX | 71,86 | -1,14 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| MINERALYS THERAPEUTICS | 36,890 | +2,33 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 41,590 | +1,41 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 33,040 | +4,62 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| KYMERA THERAPEUTICS | 89,67 | +2,12 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| IMMUNOVANT | 26,430 | +6,53 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| BIONTECH | 80,85 | +0,06 % | BioNTech SE: Erste Ergebnisse aus BioNTechs und BMS' globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs | Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, "TNBC") zeigten eine ermutigende Anti-Tumor-Aktivität... ► Artikel lesen |
ARRIVENT BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 24,420 Euro und damit +0,41 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARRIVENT BIOPHARMA INC finden Sie auf Wallstreet Online.